---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-26T09:55:58.704659'
end_time: '2025-12-26T10:03:14.686289'
duration_seconds: 435.98
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: BRCA2
  gene_symbol: BRCA2
  uniprot_accession: P51587
  protein_description: 'RecName: Full=Breast cancer type 2 susceptibility protein
    {ECO:0000305}; AltName: Full=Fanconi anemia group D1 protein;'
  gene_info: Name=BRCA2 {ECO:0000312|HGNC:HGNC:1101}; Synonyms=FACD, FANCD1;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: BRCA2. (IPR015525); BRCA2_hlx. (IPR015252); BRCA2_hlx_sf. (IPR036315);
    BRCA2_OB_1. (IPR015187); BRCA2_OB_2_dom. (IPR048262)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 22
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P51587
- **Protein Description:** RecName: Full=Breast cancer type 2 susceptibility protein {ECO:0000305}; AltName: Full=Fanconi anemia group D1 protein;
- **Gene Information:** Name=BRCA2 {ECO:0000312|HGNC:HGNC:1101}; Synonyms=FACD, FANCD1;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** BRCA2. (IPR015525); BRCA2_hlx. (IPR015252); BRCA2_hlx_sf. (IPR036315); BRCA2_OB_1. (IPR015187); BRCA2_OB_2_dom. (IPR048262)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "BRCA2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'BRCA2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **BRCA2** (gene ID: BRCA2, UniProt: P51587) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P51587
- **Protein Description:** RecName: Full=Breast cancer type 2 susceptibility protein {ECO:0000305}; AltName: Full=Fanconi anemia group D1 protein;
- **Gene Information:** Name=BRCA2 {ECO:0000312|HGNC:HGNC:1101}; Synonyms=FACD, FANCD1;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** BRCA2. (IPR015525); BRCA2_hlx. (IPR015252); BRCA2_hlx_sf. (IPR036315); BRCA2_OB_1. (IPR015187); BRCA2_OB_2_dom. (IPR048262)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "BRCA2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'BRCA2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **BRCA2** (gene ID: BRCA2, UniProt: P51587) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report on Human BRCA2 (UniProt P51587)

Plan and identity verification
- We verified the target identity: BRCA2, UniProt P51587, Homo sapiens, with aliases FANCD1/FACD, is the human breast cancer type 2 susceptibility protein. Core domains (BRC repeats; DNA-binding domain with OB folds and tower; C-terminal recombinase-binding region) and DSS1 binding described below match contemporary literature (including 2023 primary work) and reviews focused on BRCA2 structure–function, HR repair, and fork protection (kwon2023dnabindingand pages 1-2, kwon2023dnabindingand pages 2-4, chanteau2025thefunctionalanalysis pages 55-60, chanteau2025thefunctionalanalysis pages 60-64).

1) Key concepts and definitions
- Primary function. BRCA2 is a genome maintenance factor that mediates homologous recombination (HR) by loading and stabilizing the recombinase RAD51 on resected single-stranded DNA (ssDNA) to form the presynaptic filament required for homology search and strand exchange (kumpula2024theroleof pages 35-38, shah2025homologousrecombinationdeficiency pages 1-3).
- Fork protection. Beyond DSB repair, BRCA2 stabilizes RAD51 on stalled/reversed replication forks to prevent nucleolytic degradation (e.g., by MRE11) and to promote restart, a function genetically and biochemically separable but coordinated with HR (kwon2023dnabindingand pages 1-2, kwon2023dnabindingand pages 2-4).
- HRD and synthetic lethality. BRCA2 loss-of-function underlies the homologous recombination deficiency (HRD) state, which confers sensitivity to platinum agents and PARP inhibitors via synthetic lethality, an established precision-oncology paradigm (shah2025homologousrecombinationdeficiency pages 1-3, shah2025homologousrecombinationdeficiency pages 26-28, shah2025homologousrecombinationdeficiency pages 28-29).

2) Molecular architecture, partners, and mechanisms
- Domain architecture.
  • Central DNA-binding domain (DBD). The canonical DBD comprises a helical domain (HD), three OB folds (OB1–OB3), and a tower domain appendage. It binds DNA with high affinity and preferentially engages ssDNA in concert with DSS1; most pathogenic missense variants cluster in exons encoding this DBD (exons 15–26), aligning with functional hotspots resolved by saturation genome editing (SGE) (chanteau2025thefunctionalanalysis pages 60-64, chanteau2025thefunctionalanalysis pages 55-60, couch2023saturationgenomeeditingbased pages 1-4).
  • C-terminal recombinase-binding region (CTRB; exon 27). The CTRB (residues ~3260–3337) is intrinsically disordered but contains conserved FxxP motifs and a basic cluster. It binds both ssDNA and dsDNA and directly engages oligomeric RAD51. CTRB alone stimulates RAD51-mediated DNA strand exchange and enables RAD51 to utilize RPA-coated ssDNA; CTRB cooperates with the BRC repeats and DBD to promote RPA-to-RAD51 exchange and is critical for HR and fork protection from MRE11 (mirin-sensitive) degradation (Nature Communications, Jan 2023; https://doi.org/10.1038/s41467-023-36211-x) (kwon2023dnabindingand pages 1-2, kwon2023dnabindingand pages 8-10, kwon2023dnabindingand pages 2-4).
  • BRC repeats. Eight internal BRC motifs bind RAD51 with varying affinities; they modulate RAD51 oligomerization, promote ATP-bound RAD51, and seed presynaptic filament assembly together with DBD/CTRB (chanteau2025thefunctionalanalysis pages 55-60, chanteau2025thefunctionalanalysis pages 60-64).
  • DSS1-binding. A positively charged surface across HD/OB1 binds DSS1, which regulates DBD DNA interactions—enhancing ssDNA preference and constraining dsDNA binding, thereby promoting RPA→RAD51 exchange on ssDNA; DSS1 loss phenocopies BRCA2 deficiency in HR (chanteau2025thefunctionalanalysis pages 168-172, chanteau2025thefunctionalanalysis pages 60-64).
- Principal partners and pathway context.
  • RAD51 is the direct recombinase client; BRCA2’s BRC repeats and CTRB cooperate to load/stabilize RAD51 on ssDNA and at reversed forks (kwon2023dnabindingand pages 1-2, kwon2023dnabindingand pages 8-10, kwon2023dnabindingand pages 2-4).
  • PALB2 and BRCA1–BARD1 coordinate resection and BRCA2 delivery to damage sites; BRCA1–BARD1 also toggles between resection and fork protection contexts, with RAD51 levels contributing to functional balance (review context) (shah2025homologousrecombinationdeficiency pages 1-3, chanteau2025thefunctionalanalysis pages 55-60).
  • DSS1 stabilizes BRCA2 and facilitates DBD functions (chanteau2025thefunctionalanalysis pages 168-172, chanteau2025thefunctionalanalysis pages 60-64).
  • Meiosis: BRCA2 collaborates with meiotic factors (e.g., MEILB2–BRME1) to load recombinases (contextual review evidence) (shah2025homologousrecombinationdeficiency pages 1-3).
- Mechanistic synthesis. BRCA2 promotes RAD51 nucleation and growth on RPA-coated ssDNA using multivalent contacts (BRCs, DBD/OB folds, CTRB), then preserves replication forks by stabilizing RAD51 on reversed forks, preventing pathological resection and enabling restart (kwon2023dnabindingand pages 1-2, kwon2023dnabindingand pages 8-10, chanteau2025thefunctionalanalysis pages 55-60, chanteau2025thefunctionalanalysis pages 60-64).

3) Subcellular localization and regulation
- BRCA2 is predominantly nuclear and accumulates at DNA double-strand breaks, ssDNA gaps, and stressed/reversed replication forks. Its engagement is coordinated with cell-cycle DNA repair programs and with BRCA1–BARD1/CtIP-mediated resection to create the RAD51 substrate (shah2025homologousrecombinationdeficiency pages 1-3, chanteau2025thefunctionalanalysis pages 55-60).

4) Disease relevance and penetrance; second primary risks
- Cancer predisposition. Pathogenic BRCA2 variants confer high lifetime breast cancer risk and elevated risks for ovarian, prostate, and pancreatic cancers. Contemporary summaries report cumulative breast cancer risk on the order of ~69% and ovarian cancer ~17% by age 80 for protein-truncating variants, and that biallelic BRCA2 mutations cause Fanconi anemia (FANCD1), consistent with essential HR functions (kumpula2024theroleof pages 35-38).
- Variant–disease mapping (2023–2024). SGE across exons 15–26 (DBD hotspot) functionally classified 7013 single nucleotide variants (SNVs), with 955 functionally abnormal. Functionally abnormal missense variants were associated with increased breast/ovarian cancer risk (OR ~3.9) and tumors showed higher LOH (86% vs 26% for functionally normal), providing powerful evidence to reclassify many VUS and to refine risk management (Dec 2023 preprint; https://doi.org/10.21203/rs.3.rs-3736200/v1) (couch2023saturationgenomeeditingbased pages 1-4).
- Second primary risks. Contemporary large-scale HRD/BRCA-focused reviews and risk syntheses support elevated second primary risks in BRCA1/2 carriers, notably contralateral breast cancer and ovarian cancer after a first breast cancer; risk magnitudes vary by gene and sex (contextual review) (shah2025homologousrecombinationdeficiency pages 26-28, shah2025homologousrecombinationdeficiency pages 28-29).

5) Recent developments and latest research (emphasis 2023–2024)
- Structural–mechanistic advance: BRCA2 CTRB (exon 27) mechanistic dissection. High-quality 2023 work demonstrated direct DNA binding and RAD51 engagement by CTRB, and its cooperation with BRC/DBD in presynaptic filament formation and fork protection; separation-of-function mutants showed DNA-binding and RAD51-binding motifs are both required (Nature Communications, Jan 2023; https://doi.org/10.1038/s41467-023-36211-x) (kwon2023dnabindingand pages 1-2, kwon2023dnabindingand pages 8-10, kwon2023dnabindingand pages 2-4).
- High-throughput variant interpretation: SGE of BRCA2 DBD. A Dec 2023 SGE study functionally assayed 97% of possible SNVs across exons 15–26, enabling classification of 700 SNVs as pathogenic/likely pathogenic and 4862 as benign/likely benign when integrated with ClinGen/ACMG frameworks—substantially reducing VUS burden (https://doi.org/10.21203/rs.3.rs-3736200/v1) (couch2023saturationgenomeeditingbased pages 1-4).
- HRD testing landscape and variability. Reviews from 2024–2025 synthesize inter-assay discordances across genomic HRD tests (e.g., gLOH thresholds, scar scores, HRDetect) and argue for complementary functional assays such as RAD51 foci to improve predictive value for PARP inhibitor benefit (shah2025homologousrecombinationdeficiency pages 28-29, shah2025homologousrecombinationdeficiency pages 8-9, shah2025homologousrecombinationdeficiency pages 25-26).

6) Current applications and real-world implementation
- Germline/somatic testing. BRCA2 testing guides prevention (enhanced surveillance, risk-reducing surgery) and treatment selection (PARP inhibitors, platinum) in breast, ovarian, prostate, and pancreatic cancers; non-BRCA HRD markers can extend PARP benefit but require robust validation (kumpula2024theroleof pages 35-38, shah2025homologousrecombinationdeficiency pages 26-28, shah2025homologousrecombinationdeficiency pages 28-29).
- PARP inhibitor indications. HRD-positive and particularly BRCA1/2-mutated high-grade serous ovarian carcinoma (HGSOC) show high response rates (e.g., 60–80% ORR reported) and progression-free survival benefits on PARPi; similar benefits are seen in subsets of breast, prostate, and pancreatic cancers (review synthesis) (shah2025homologousrecombinationdeficiency pages 26-28, shah2025homologousrecombinationdeficiency pages 28-29).
- HRD assays in practice. Commercial genomic-scarring assays (e.g., myChoice CDx, FoundationOne CDx) and research algorithms (e.g., HRDetect) are used to infer HRD, but exhibit notable variability, emphasizing the value of integrating genomic scars with functional RAD51 assays and careful thresholding for clinical decision-making (shah2025homologousrecombinationdeficiency pages 28-29, shah2025homologousrecombinationdeficiency pages 25-26).

7) Expert opinions and analysis from authoritative sources
- Mechanistic expert synthesis. The 2023 Nature Communications study provides direct molecular evidence for CTRB’s dual DNA/RAD51 engagement as integral to HR and fork protection, refining the canonical model of BRCA2-mediated RAD51 loading and fork stabilization (https://doi.org/10.1038/s41467-023-36211-x) (kwon2023dnabindingand pages 1-2, kwon2023dnabindingand pages 8-10, kwon2023dnabindingand pages 2-4).
- Variant-interpretation ecosystem. The 2023 SGE preprint outlines a comprehensive framework aligning functional scores with ClinGen/ACMG classification, supporting widespread clinical adoption to resolve BRCA2 DBD missense VUS (https://doi.org/10.21203/rs.3.rs-3736200/v1) (couch2023saturationgenomeeditingbased pages 1-4). Parallel SGE/DMS efforts on RAD51C and guidance for functional evidence (PS3/BS3) underscore a rapidly maturing field (olveraleon2024comprehensivesaturationgenome pages 26-27).
- HRD testing consensus gaps. Contemporary HRD reviews highlight the need for assay harmonization, improved detection of non-BRCA HRD, and integration of functional biomarkers to optimize patient selection for PARPi and combinations (shah2025homologousrecombinationdeficiency pages 28-29, shah2025homologousrecombinationdeficiency pages 8-9, shah2025homologousrecombinationdeficiency pages 25-26).

8) Relevant statistics and data from recent studies
- BRCA2 penetrance and spectrum. Summaries from recent hereditary-breast cancer research report cumulative breast cancer risk ~69% and ovarian cancer ~17% to age 80 for protein-truncating BRCA2 variants; BRCA1/2 account for ~15–20% of hereditary breast cancer; biallelic BRCA2 causes FANCD1 (kumpula2024theroleof pages 35-38).
- Functional classification yield from SGE. 7013 BRCA2 DBD SNVs functionally scored; 955 abnormal; abnormal missense pool associated with increased breast/ovarian cancer risk (OR 3.89, 95% CI 2.77–5.51); LOH in 86% of tumors for abnormal variants vs 26% for normal—substantially enabling clinical reclassification (Dec 2023; https://doi.org/10.21203/rs.3.rs-3736200/v1) (couch2023saturationgenomeeditingbased pages 1-4).
- HRD/PARPi outcomes. Reviews collating trial and practice data report high PARPi response rates in BRCA1/2-mutated HGSOC (e.g., 60–80% ORR) and PFS improvements; HRD-positive (non-BRCA) cohorts derive benefit but with variable effect sizes; resistance mechanisms include BRCA reversion and replication fork stabilization (shah2025homologousrecombinationdeficiency pages 26-28, shah2025homologousrecombinationdeficiency pages 28-29).

9) Where BRCA2 works in the cell and pathway placement
- Site of action. BRCA2 functions in the nucleus at resected DSBs, ssDNA gaps, and reversed forks—physically loading and stabilizing RAD51 onto ssDNA and protecting regressed forks from MRE11-mediated degradation (kwon2023dnabindingand pages 1-2, kwon2023dnabindingand pages 8-10, chanteau2025thefunctionalanalysis pages 55-60).
- Pathways. It operates in the RAD51-dependent HR pathway downstream of MRN/CtIP/EXO1 resection and within replication-stress responses that promote fork reversal and protection—interfacing with BRCA1–BARD1, PALB2, RAD51 paralogs, and DSS1 (shah2025homologousrecombinationdeficiency pages 1-3, chanteau2025thefunctionalanalysis pages 55-60, chanteau2025thefunctionalanalysis pages 168-172).

Key artifact (summary table)
| Category | Specifics | Key Evidence / Notes | Year | Source (journal/name) with URL |
|---|---|---|---:|---|
| Domains | BRC repeats (multiple BRC motifs), DNA-binding domain (DBD) with OB folds + tower domain, DSS1-binding site, C-terminal Recombinase-Binding region (CTRB / exon 27) | Functional mapping of the DBD hotspot (exons 15–26) by saturation genome editing; domain roles inferred from functional assays linking DBD/CTRB to RAD51 engagement and fork protection (SGE shows DBD missense LOF associates with cancer risk) (couch2023saturationgenomeeditingbased pages 1-4, kumpula2024theroleof pages 35-38, shah2025homologousrecombinationdeficiency pages 1-3) | 2023–2024 | Couch et al. (2023) SGE preprint — https://doi.org/10.21203/rs.3.rs-3736200/v1; Kumpula 2024 (role summary) (couch2023saturationgenomeeditingbased pages 1-4, kumpula2024theroleof pages 35-38) |
| Principal partners | RAD51 (direct binding/filament stabilization), PALB2 (bridging to BRCA1), BRCA1–BARD1 (resection/protection axis), DSS1 (stabilizes BRCA2), meiosis-specific MEILB2–BRME1 interaction | BRCA2 mediates RAD51 loading; reviews and functional studies list PALB2/BRCA1–BARD1/DSS1 as core interactors; RAD51-paralog and RAD51C functional mapping work supports collaboration in filament dynamics (shah2025homologousrecombinationdeficiency pages 1-3, olveraleon2024comprehensivesaturationgenome pages 26-27) | 2024–2025 | Shah et al. (2025) HRD review preprint — https://doi.org/10.20944/preprints202504.0229.v1; Olvera-León et al. (RAD51C SGE) 2024 (shah2025homologousrecombinationdeficiency pages 1-3, olveraleon2024comprehensivesaturationgenome pages 26-27) |
| Core functions | Loads/stabilizes RAD51 on RPA-coated ssDNA for homologous recombination (HDR); protects stalled/reversed replication forks from nucleolytic degradation (fork protection) | Mechanistic role in RAD51 loading and fork protection is central to BRCA2 tumor-suppressor activity; DBD/CTRB perturbation → defective HDR and increased cancer association in SGE data (couch2023saturationgenomeeditingbased pages 1-4, kumpula2024theroleof pages 35-38, shah2025homologousrecombinationdeficiency pages 1-3) | 2023–2025 | Kumpula 2024 (functional summary) & Couch et al. (2023) SGE (kumpula2024theroleof pages 35-38, couch2023saturationgenomeeditingbased pages 1-4) |
| Cellular localization & regulation | Predominantly nuclear; recruited to DNA damage sites and stalled forks; activity coordinated with cell-cycle DNA repair programs and with PALB2/BRCA1-mediated resection machinery | Reviews and mechanistic summaries describe BRCA2 acting at DSBs and replication forks with cell-cycle-dependent repair engagement; implications for HRD phenotype and therapy response (shah2025homologousrecombinationdeficiency pages 1-3, kumpula2024theroleof pages 35-38) | 2024–2025 | Shah et al. (2025) review — https://doi.org/10.20944/preprints202504.0229.v1 (shah2025homologousrecombinationdeficiency pages 1-3) |
| Key 2023–2024 developments | 1) Saturation genome editing (SGE) of BRCA2 DBD enabling large-scale functional classification of SNVs; 2) Growing recognition of HRD assay variability and need for harmonization; 3) Functional RAD51 assays (RAD51 foci) as complements to genomic HRD tests | SGE provided high-resolution functional scores linking DBD variants to pathogenicity and LOH in tumors; HRD-testing reviews highlight assay discordance and the value of combining genomic scars with functional readouts to predict PARPi response (couch2023saturationgenomeeditingbased pages 1-4, shah2025homologousrecombinationdeficiency pages 28-29, shah2025homologousrecombinationdeficiency pages 8-9, shah2025homologousrecombinationdeficiency pages 25-26) | 2023–2024 (SGE 2023; HRD assay discussions 2024–2025) | Couch et al. (2023) SGE preprint https://doi.org/10.21203/rs.3.rs-3736200/v1; Shah et al. (2025) HRD review https://doi.org/10.20944/preprints202504.0229.v1 (couch2023saturationgenomeeditingbased pages 1-4, shah2025homologousrecombinationdeficiency pages 28-29) |
| Clinical applications | Germline/somatic BRCA2 testing guides risk management (surveillance, risk-reducing surgery) and therapy (PARP inhibitors in breast/ovarian/prostate/pancreatic cancer); HRD assays (genomic scars, gLOH, HRDetect) used to expand PARPi indications but show inter-assay variability | Penetrance & risk estimates summarized in recent reviews; real-world studies show variable testing and PARPi uptake; HRD assays predict PARPi benefit but discordance across platforms necessitates integrated approaches (kumpula2024theroleof pages 35-38, shah2025homologousrecombinationdeficiency pages 26-28, shah2025homologousrecombinationdeficiency pages 28-29) | 2023–2024 (clinical guideline activity) | Kumpula 2024 (penetrance/clinical impact) and Shah et al. (2025) HRD/clinical assay discussion (kumpula2024theroleof pages 35-38, shah2025homologousrecombinationdeficiency pages 26-28, shah2025homologousrecombinationdeficiency pages 28-29) |


*Table: Compact table summarizing BRCA2 domains, partners, core functions, localization, recent 2023–2024 developments, and clinical applications with key supporting evidence (context IDs).*

URLs and publication dates (selection)
- Kwon et al., Nature Communications, Jan 2023. URL: https://doi.org/10.1038/s41467-023-36211-x (CTRB/RAD51–DNA engagement; HR/fork protection) (kwon2023dnabindingand pages 1-2, kwon2023dnabindingand pages 8-10, kwon2023dnabindingand pages 2-4).
- Couch et al., Research Square preprint, Dec 2023. URL: https://doi.org/10.21203/rs.3.rs-3736200/v1 (BRCA2 DBD SGE; variant classification and clinical integration) (couch2023saturationgenomeeditingbased pages 1-4).
- Shah et al., Preprints (MDPI), Apr 2025. URL: https://doi.org/10.20944/preprints202504.0229.v1 (HRD biomarker landscape, assay variability, PARPi implications; bridges 2023–2024 literature) (shah2025homologousrecombinationdeficiency pages 28-29, shah2025homologousrecombinationdeficiency pages 8-9, shah2025homologousrecombinationdeficiency pages 25-26, shah2025homologousrecombinationdeficiency pages 26-28, shah2025homologousrecombinationdeficiency pages 1-3).

Conclusion
Human BRCA2 (P51587) is a nuclear HR mediator and fork-protection factor whose multivalent architecture—BRC repeats, OB folds/tower DBD, and CTRB—coordinates RAD51 loading on ssDNA and stabilization at stalled forks. Recent (2023–2024) advances provide high-resolution functional maps (SGE) of DBD variants for clinical interpretation and mechanistic dissection of the CTRB’s dual DNA/RAD51-binding roles in HR and fork preservation. Clinically, BRCA2 underpins HRD-directed therapy: germline/somatic testing informs prevention and selection of PARP inhibitors and platinum, though HRD test heterogeneity argues for integrated genomic and functional biomarkers. These contemporary data refine mechanistic understanding and improve clinical decision-making for individuals with BRCA2 variants and for tumors exhibiting BRCA2-associated HRD (kwon2023dnabindingand pages 1-2, kwon2023dnabindingand pages 8-10, couch2023saturationgenomeeditingbased pages 1-4, shah2025homologousrecombinationdeficiency pages 28-29).

References

1. (kwon2023dnabindingand pages 1-2): Youngho Kwon, Heike Rösner, Weixing Zhao, Platon Selemenakis, Zhuoling He, Ajinkya S. Kawale, Jeffrey N. Katz, Cody M. Rogers, Francisco E. Neal, Aida Badamchi Shabestari, Valdemaras Petrosius, Akhilesh K. Singh, Marina Z. Joel, Lucy Lu, Stephen P. Holloway, Sandeep Burma, Bipasha Mukherjee, Robert Hromas, Alexander Mazin, Claudia Wiese, Claus S. Sørensen, and Patrick Sung. Dna binding and rad51 engagement by the brca2 c-terminus orchestrate dna repair and replication fork preservation. Nature Communications, Jan 2023. URL: https://doi.org/10.1038/s41467-023-36211-x, doi:10.1038/s41467-023-36211-x. This article has 49 citations and is from a highest quality peer-reviewed journal.

2. (kwon2023dnabindingand pages 2-4): Youngho Kwon, Heike Rösner, Weixing Zhao, Platon Selemenakis, Zhuoling He, Ajinkya S. Kawale, Jeffrey N. Katz, Cody M. Rogers, Francisco E. Neal, Aida Badamchi Shabestari, Valdemaras Petrosius, Akhilesh K. Singh, Marina Z. Joel, Lucy Lu, Stephen P. Holloway, Sandeep Burma, Bipasha Mukherjee, Robert Hromas, Alexander Mazin, Claudia Wiese, Claus S. Sørensen, and Patrick Sung. Dna binding and rad51 engagement by the brca2 c-terminus orchestrate dna repair and replication fork preservation. Nature Communications, Jan 2023. URL: https://doi.org/10.1038/s41467-023-36211-x, doi:10.1038/s41467-023-36211-x. This article has 49 citations and is from a highest quality peer-reviewed journal.

3. (chanteau2025thefunctionalanalysis pages 55-60): A Chanteau. The functional analysis of canonical and non-canonical brca2 in homologous recombination repair. Unknown journal, 2025.

4. (chanteau2025thefunctionalanalysis pages 60-64): A Chanteau. The functional analysis of canonical and non-canonical brca2 in homologous recombination repair. Unknown journal, 2025.

5. (kumpula2024theroleof pages 35-38): T Kumpula. The role of rare copy number variants and other candidate alleles in hereditary breast cancer susceptibility. Unknown journal, 2024.

6. (shah2025homologousrecombinationdeficiency pages 1-3): Bhaumik Shah, Muhammad Hussain, and Anjali Seth. Homologous recombination deficiency in ovarian and breast cancers: biomarkers, diagnosis and treatment. Apr 2025. URL: https://doi.org/10.20944/preprints202504.0229.v1, doi:10.20944/preprints202504.0229.v1.

7. (shah2025homologousrecombinationdeficiency pages 26-28): Bhaumik Shah, Muhammad Hussain, and Anjali Seth. Homologous recombination deficiency in ovarian and breast cancers: biomarkers, diagnosis and treatment. Apr 2025. URL: https://doi.org/10.20944/preprints202504.0229.v1, doi:10.20944/preprints202504.0229.v1.

8. (shah2025homologousrecombinationdeficiency pages 28-29): Bhaumik Shah, Muhammad Hussain, and Anjali Seth. Homologous recombination deficiency in ovarian and breast cancers: biomarkers, diagnosis and treatment. Apr 2025. URL: https://doi.org/10.20944/preprints202504.0229.v1, doi:10.20944/preprints202504.0229.v1.

9. (couch2023saturationgenomeeditingbased pages 1-4): Fergus Couch, Huaizhi Huang, Chunling Hu, Jie Na, Steven Hart, Rohan Gnanaolivu, Mohamed Abozaid, Tara Rao, Yohannes Tecleab, Tina Pesaran, Paulo Lyra, Rachid Karam, Siddhartha Yadav, Susan Domchek, Miguel de la Hoya, Mark Robson, Miika Mehine, Chaitanya Bandlamudi, Diana Mandelker, Alvaro Monteiro, Nicholas Boddicker, Wenan Chen, and Marcy Richardson. Saturation genome editing-based functional evaluation and clinical classification of brca2 single nucleotide variants. Dec 2023. URL: https://doi.org/10.21203/rs.3.rs-3736200/v1, doi:10.21203/rs.3.rs-3736200/v1.

10. (kwon2023dnabindingand pages 8-10): Youngho Kwon, Heike Rösner, Weixing Zhao, Platon Selemenakis, Zhuoling He, Ajinkya S. Kawale, Jeffrey N. Katz, Cody M. Rogers, Francisco E. Neal, Aida Badamchi Shabestari, Valdemaras Petrosius, Akhilesh K. Singh, Marina Z. Joel, Lucy Lu, Stephen P. Holloway, Sandeep Burma, Bipasha Mukherjee, Robert Hromas, Alexander Mazin, Claudia Wiese, Claus S. Sørensen, and Patrick Sung. Dna binding and rad51 engagement by the brca2 c-terminus orchestrate dna repair and replication fork preservation. Nature Communications, Jan 2023. URL: https://doi.org/10.1038/s41467-023-36211-x, doi:10.1038/s41467-023-36211-x. This article has 49 citations and is from a highest quality peer-reviewed journal.

11. (chanteau2025thefunctionalanalysis pages 168-172): A Chanteau. The functional analysis of canonical and non-canonical brca2 in homologous recombination repair. Unknown journal, 2025.

12. (shah2025homologousrecombinationdeficiency pages 8-9): Bhaumik Shah, Muhammad Hussain, and Anjali Seth. Homologous recombination deficiency in ovarian and breast cancers: biomarkers, diagnosis and treatment. Apr 2025. URL: https://doi.org/10.20944/preprints202504.0229.v1, doi:10.20944/preprints202504.0229.v1.

13. (shah2025homologousrecombinationdeficiency pages 25-26): Bhaumik Shah, Muhammad Hussain, and Anjali Seth. Homologous recombination deficiency in ovarian and breast cancers: biomarkers, diagnosis and treatment. Apr 2025. URL: https://doi.org/10.20944/preprints202504.0229.v1, doi:10.20944/preprints202504.0229.v1.

14. (olveraleon2024comprehensivesaturationgenome pages 26-27): R Olvera-León, F Zhang, V Offord, Y Zhao, and HK Tan. Comprehensive saturation genome editing of rad51c provides precise functional classification within a spectrum of variant effects. Unknown journal, 2024.

## Citations

1. shah2025homologousrecombinationdeficiency pages 1-3
2. kumpula2024theroleof pages 35-38
3. couch2023saturationgenomeeditingbased pages 1-4
4. olveraleon2024comprehensivesaturationgenome pages 26-27
5. kwon2023dnabindingand pages 1-2
6. kwon2023dnabindingand pages 2-4
7. chanteau2025thefunctionalanalysis pages 55-60
8. chanteau2025thefunctionalanalysis pages 60-64
9. shah2025homologousrecombinationdeficiency pages 26-28
10. shah2025homologousrecombinationdeficiency pages 28-29
11. kwon2023dnabindingand pages 8-10
12. chanteau2025thefunctionalanalysis pages 168-172
13. shah2025homologousrecombinationdeficiency pages 8-9
14. shah2025homologousrecombinationdeficiency pages 25-26
15. https://doi.org/10.1038/s41467-023-36211-x
16. https://doi.org/10.21203/rs.3.rs-3736200/v1
17. https://doi.org/10.21203/rs.3.rs-3736200/v1;
18. https://doi.org/10.20944/preprints202504.0229.v1;
19. https://doi.org/10.20944/preprints202504.0229.v1
20. https://doi.org/10.1038/s41467-023-36211-x,
21. https://doi.org/10.20944/preprints202504.0229.v1,
22. https://doi.org/10.21203/rs.3.rs-3736200/v1,